← Back to VYNE

VYNE Therapeutics Inc. - Common Stock financial statements

Annual and standalone quarterly facts filed by the company with the SEC. Monetary values are shown in USD millions; per-share values use USD.

Filed statements

USD; millions except EPSMar 2026Filed 03/06/2026Jun 2025Filed 14/08/2025Mar 2025Filed 03/06/2026Sep 2024Filed 07/11/2024Jun 2024Filed 14/08/2025Mar 2024Filed 08/05/2025Sep 2023Filed 07/11/2024Jun 2023Filed 14/08/2024
$0.1$0.1$0.2$0.1$0.2$0.1$0.1$0.1
−$3.6−$5.8−$8.6−$12−$9.4−$6.2−$6.6−$10
−$0.08−$0.13−$0.20−$0.29−$0.22−$0.15−$2.01−$3.09
434343433.33.3

Trend

Revenue

Source: SEC EDGAR Company Facts. Values are normalized from issuer-filed US GAAP or IFRS XBRL facts. Missing cells stay missing; cumulative interim cash flows are not converted into estimated quarters.